AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission ...

Investigators evaluated emraclidine in patients with schizophrenia who are experiencing an acute exacerbation in two placebo-controlled Phase II trials, which included EMPOWER-1 and EMPOWER-2. The ...

Emraclidine is a potential novel M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer's disease psychosis as a once-daily medication without the need ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The ...

Emraclidine is also in phase 1 for Alzheimer's disease psychosis, which also has FDA Fast Track designation. However, this is a much smaller market than the schizophrenia indication would have been.

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025.The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

AbbVie’s treatment, emraclidine, which it got the drug through its $9 billion acquisition of Cerevel Therapeutics, failed to significantly help patients. Skip to Main Content.

Emraclidine performed worse than in Cerevel’s phase 1b trial, when the biotech tracked improvements on PANSS of 19.5 and 17.9 points, but placebo response was the main difference between the ...

AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an ...